Novavax (NVAX) Covid-19 Vaccine Induces Immune Response in First Human Study, Company Says - DJ
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Join SI Premium – FREE
(Updated - August 4, 2020 4:02 PM EDT)
Novavax (NASDAQ: NVAX) Covid-19 Vaccine Induces Immune Response in First Human Study, Company Says - DJ
- Data Supports Further Tests, Plans Large Study in Fall
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca's Wainua fails primary endpoint in heart trial
- Evaxion shares preclinical data for CMV vaccine program EVX-V1
- Solaris Energy Infrastructure to Join S&P SmallCap 600
Create E-mail Alert Related Categories
Corporate News, FDA, Hot Corp. News, Hot FDA News, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
